**6. Conclusions**

Thus, the initiation of lipid-lowering therapy in familial hypercholesterolemia from childhood is of great importance for reducing the cumulative effect of LDL cholesterol and increasing the patient's life expectancy. When answering questions regarding the treatment of children with dyslipidemia, one should take into account the compelling reasons to follow international recommendations and use statins for familial hypercholesterolemia from the age of 8–10 years, with monitoring of the recommended clinical and biochemical markers under the supervision of a physician. There is currently a need to continue randomized trials to prove the lifelong benefit of low LDL cholesterol in patients with familial hypercholesterolemia.
